Drug interaction between clopidogrel and proton pump inhibitors

Area of Science:

• Pharmacology and Drug Interactions
• Cardiovascular Medicine

Background:

• Dual antiplatelet therapy (DAPT) with clopidogrel and aspirin reduces cardiac events.
• Patients on DAPT have increased bleeding risk, often leading to proton pump inhibitor (PPI) co-prescription for gastrointestinal prophylaxis.

Purpose of the Study:

• To review the metabolism of various PPIs.
• To examine existing data on the drug-drug interaction between PPIs and clopidogrel.

Main Methods:

• Review of scientific literature on PPI metabolism and clopidogrel drug interactions.
• Analysis of studies investigating the impact of PPIs on clopidogrel's antiplatelet activity.

Main Results:

• Clopidogrel is a prodrug activated by the cytochrome P450 system.
• PPIs are also metabolized by cytochrome P450 enzymes.
• Emerging data suggest PPIs may diminish clopidogrel's antiplatelet efficacy.

Conclusions:

• The cytochrome P450-mediated metabolism of PPIs raises concerns about potential interactions with clopidogrel.
• Further research is needed to fully elucidate the clinical significance of PPI-clopidogrel interactions on cardiovascular outcomes.